Prelude Therapeutics Reports $5.7 Million Revenue in Q2 2026, Continues to Operate at a Loss

Prelude Therapeutics Incorporated reported its financial results for the second quarter of 2026, revealing a revenue of $5.7 million for the three months ended June 30, 2026, compared to no revenue in the same period of the previous year. For the six months ended June 30, 2026, the company generated $10.3 million in revenue, attributed to its Exclusive Option Agreement with Incyte. Despite this revenue, Prelude continues to operate at a loss, with a net loss of $13.9 million for the quarter and $24.3 million for the first half of the year, a significant improvement from the $31.2 million and $63.3 million losses reported in the respective periods of 2025.

The company’s operating expenses decreased notably, with total operating expenses for the second quarter of 2026 at $21.2 million, down from $32.2 million in the same quarter of 2025. This reduction was primarily driven by lower research and development costs, which fell from $25.8 million to $16.1 million, reflecting a strategic decision to pause certain clinical trials and a reduction in workforce implemented in late 2025. General and administrative expenses also decreased from $6.4 million to $5.0 million, contributing to the overall reduction in operating costs.

Prelude's balance sheet as of June 30, 2026, showed total assets of $189.4 million, an increase from $141.3 million at the end of 2025. The company had cash and cash equivalents of $26.3 million, alongside marketable securities valued at $125.4 million. The total liabilities decreased to $55.6 million from $72.7 million, primarily due to a reduction in current liabilities. The company’s stockholders’ equity rose to $133.7 million, up from $68.6 million at the end of 2025, reflecting the successful capital raise through the sale of common stock and pre-funded warrants in April 2026.

Looking ahead, Prelude anticipates continued investment in its research and development efforts, particularly in advancing its pipeline of precision oncology candidates. The company has indicated that it expects to incur additional losses as it progresses through clinical trials and seeks regulatory approvals. Prelude believes its current cash position, along with marketable securities, will be sufficient to fund operations for at least the next twelve months. However, the company plans to explore additional funding options, including equity offerings and collaborations, to support its ongoing development activities and potential commercialization efforts.